Division of Oncology, S.Orsola-Malpighi Hospital, Bologna, Italy.
Oncology Unit, Macerata Hospital, via Santa Lucia 2, Macerata, Italy.
Target Oncol. 2018 Dec;13(6):705-714. doi: 10.1007/s11523-018-0601-2.
Cytoreductive nephrectomy in metastatic renal cell carcinoma (mRCC) patients has been common clinical practice due to evidence that resection of the primary tumor results in a survival benefit regardless of systemic treatment. Recently, the first large phase III randomized, non-inferiority prospective clinical trial evaluating this surgical approach demonstrated that systemic treatment alone was not inferior to primary surgery plus systemic treatment.
Our aim was to evaluate if cytoreductive nephrectomy results in a survival benefit over systemic treatment alone in patients with mRCC and in specific subgroups, including patients with brain metastases, poor performance status, poor prognosis according to IMDC or MSKCC criteria, and clear cell and non-clear cell histologies.
We identified 16 published studies providing complete data for the comparison between cytoreductive nephrectomy + systemic treatment versus systemic treatment alone, and selected 9 for subgroup analysis. The inverse variance technique was applied for the meta-analysis of hazard ratios (HR), and, due to the intrinsic heterogeneity of the data, we adopted a random effects model. Risk of bias among the studies was estimated by the Newcastle-Ottawa Scale (NOS).
Our analysis suggested a survival benefit for patients receiving cytoreductive nephrectomy (pooled HR of 0.48, 95% confidence interval of 0.42-0.56) in the overall population. Survival advantages were also observed in patients with clear cell and non-clear renal cell carcinoma, while no benefit was evident in patients with brain metastasis, poor performance status, and poor risk.
Cytoreductive nephrectomy seems to result in a survival benefit in both clear cell and non-clear cell histology, while no survival advantage was found in patients with specific clinical features. Despite a high level of heterogeneity, our results highlight the importance of a good selection of patients to whom a primary surgical approach could be proposed.
在转移性肾细胞癌(mRCC)患者中,细胞减灭性肾切除术已成为常见的临床实践,因为有证据表明切除原发肿瘤可带来生存获益,无论是否进行系统治疗。最近,首次大型 III 期随机、非劣效性前瞻性临床试验评估了这种手术方法,结果表明单独进行系统治疗并不劣于原发肿瘤手术联合系统治疗。
我们旨在评估细胞减灭性肾切除术是否在 mRCC 患者中以及特定亚组中(包括脑转移、表现状态差、根据 IMDC 或 MSKCC 标准预后不良以及透明细胞和非透明细胞组织学)带来优于单独系统治疗的生存获益。
我们确定了 16 项发表的研究,这些研究提供了细胞减灭性肾切除术+系统治疗与单独系统治疗比较的完整数据,并选择了 9 项进行亚组分析。应用逆方差技术进行危险比(HR)的荟萃分析,由于数据内在的异质性,我们采用了随机效应模型。使用纽卡斯尔-渥太华量表(NOS)评估研究中的偏倚风险。
我们的分析表明,接受细胞减灭性肾切除术的患者具有生存获益(总体人群的合并 HR 为 0.48,95%置信区间为 0.42-0.56)。在透明细胞和非透明肾细胞癌患者中也观察到生存优势,而在有脑转移、表现状态差和高风险的患者中则未观察到获益。
细胞减灭性肾切除术似乎在透明细胞和非透明细胞组织学中都带来了生存获益,而在具有特定临床特征的患者中则未观察到生存优势。尽管存在高度的异质性,但我们的结果强调了对可能受益于主要手术方法的患者进行良好选择的重要性。